Biofrontera AG

  • WKN: 604611
  • ISIN: DE0006046113
  • Land: Deutschland

Nachricht vom 09.04.2020 | 18:30

Biofrontera AG:

DGAP-News: Biofrontera AG / Key word(s): Miscellaneous
09.04.2020 / 18:30
The issuer is solely responsible for the content of this announcement.

Biofrontera announces conference call to be held on April 21, 2020 to discuss full year 2019 financial results

Leverkusen, Germany, April 9, 2020 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock
Exchange: B8F) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the full year 2019 on Monday, April 20, 2020.

Conference calls for shareholders and interested investors will be held on Tuesday, April 21, 2020, at the following times:

In German, April 21, 2020 at 10:00 am CEST (4:00 am EST)
Dial-in number Germany: +49 69201744220
Conference code: 26923241#

In English, April 21, 2020 at 2:00 pm CEST (8:00 am EST)
Dial-in number USA: +1 8774230830
Dial-in number UK: +44 2030092470
Conference code: 92360370#

Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.
-End-

For enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer


+49 (0) 214 87 63 2 0
ir@biofrontera.com
IR UK: Seton Services
Toni Vallen

+44 (0) 207 229 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas

+1 646-536-7035
+1 508-280-6592

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication XepiTM for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.



09.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

EQS Group: Rating lautet Kaufen

Die Vorzeichen für die EQS Group AG sind positiv. Ein wesentlicher Umsatztreiber für das Jahr 2020 sollte die Migration von Bestandskunden vom COCKPIT in das COCKPIT 2.0 bedeuten. Darüber hinaus erwarten wir ein gutes Wachstum in den übrigen Bereichen, da die EQS mit vielen Produkten auch von der Coronakrise profitieren kann. So werden z. B. Online-Hauptversammlungen, Webcasts und Telefonkonferenzen vermehrt gebucht: Unseres Erachtens sollte es auch zu einer höhere Anzahl an Pflichtmeldungen von Unternehmen kommen. Unser Kursziel liegt bei 91,50 €, das Rating lautet weiter Kaufen.

News im Fokus

Deutsche Lufthansa AG: Lufthansa Aufsichtsrat verschiebt Entscheidung über Einberufung zur Hauptversammlung

27. Mai 2020, 14:59

Aktuelle Research-Studie

Aves One AG

Original-Research: Aves One AG (von GBC AG): Buy

27. Mai 2020